Salvage surgery following downstaging of advanced non-small cell lung cancer by targeted therapy.

ABSTRACT:

Background

Advanced non-small cell lung cancer (NSCLC) accounts for a high proportion of lung cancer cases. Targeted therapy improve the survival in these patients, but acquired drug resistance will inevitably occur. If tumor downstaging is achieved after targeted therapy, could surgical resection before drug resistance improve clinical benefits for patients with advanced NSCLC? Here, we conducted a clinical trial showing that for patients with advanced driver gene mutant NSCLC who did not progress after targeted therapy, salvage surgery (SS) could improve progression-free survival (PFS). Herein, we retrospectively reviewed our former clinical trial and thoracic cancer database in our medical institutions.

Methods

We identified patients with advanced driver gene mutant NSCLC

SUBMITTER: Li K 

PROVIDER: S-EPMC8327695 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature